Patients on semaglutide injections often report 48 pounds of total loss by the end of week 8, though individual results vary based on diet adherence, activity level, and genetic factors
Journal of Obesity & Metabolic Syndrome, 27(1), 424
Constipation happens when the typical muscle actions in the bowel slow down
Its design is based on the sequence of a natural glucose-dependent insulinotropic polypeptide (GIP) and simultaneously activates the glucagon-like peptide-1 (GLP-1) receptor, hence the name "twincretin." The drug first entered clinical research in 2016, with Eli Lilly initiating a Phase I clinical trial to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in obese or overweight subjects with related comorbidities
Look out for our next Insight about GLP-1 insurance coverage of marketed products, coming in June